AVEA, the longevity supplement start-up with the aim to improve health-span, announces the closing of a 2.5 million CHF seed financing round led by Maximon, The Longevity Company Builder and its Longevity Co-Investment Fund.
After a year of research, AVEA launched its first products in February 2022. This first funding will support the company's rapid growth across Switzerland, Germany, Austria and the UK, power scientific research, propel the development of innovative longevity-focused supplements and help establish the brand as a leader in Europe.
AVEA’s strategy is to leverage a science-based approach to help customers make sense of the overwhelming health and wellness supplement market. The main idea behind AVEA’s products is to focus on ingredients that act in synergy to slow ageing at the cellular level, because when your cells work better, your whole body works better. The start-up has enlisted award-winning scientists and researchers in the field of longevity to produce the highest quality, comprehensive and scientifically-backed supplement line on the European market for those who wish to optimize their long-term health as well as slow and even reverse some of the signs of ageing.
Two products are already available. NMN is formulated with 250mg of NMN (Nicotinamide Mononucleotide). According to Avea scientific research has shown that NMN is one of the most promising supplements for safely and effectively slowing the signs ageing, increasing energy, and supporting nearly every organ in the body. Booster features a combination of five carefully selected ingredients. Together, these active ingredients work to prevent and slow the signs of ageing at the cellular level. Each soft gel capsule contains a total of 400mg of bioavailable ingredients.
The deal was made public in Davos during this year's "World Economic Forum" where Maximon hosted an event for investors in the field of longevity. Dr. Tobias Reichmuth, serial entrepreneur and founding partner of Maximon, states: “The global longevity market is worth $8 trillion. The longevity field is the future of healthcare and we believe AVEA will play an important role in the industry.”
“As we are seeking to build and launch longevity companies with Maximon, Avea was a clear case for us to invest in. We are at an inflection point where people not only look at supplements to boost health and vitamin levels, but start to actively invest in a longer healthy lifespan. This is the opportunity that Avea is well positioned to capture and we are excited to be part of this story“ adds Caroline Wagner, chairwoman of the Board of Avea and founding partner of Maximon.
(Press release / SK)
Photo L-R: Avea founders Sophie Chabloz, Pascal Rode, Teresa Budetta
Florjan Munih @ 03.06.2022 07:29
Longevity Expected of human living ican be close to 220 years. NMN affects only one of the processes in the mitochondria. However, it is necessary to optimize all processes at once. In addition, it is necessary to restore the whole body and all the cells in it, which looks like this: 1) Clean the blood vessels to the capillaries. 2) Feeding special foods only when you are working. 3) Rejuvenated cell function and maximize ATP production. 4) Gene therapy to prolong telomeres. Each of these points prolongs life. If men optimize all processes and are performed permanently, the body slows down aging and optimizes physical and mental abilities. This is influenced by the daily ATP surplus generated. This was my vision of all the necessary bodily processes for longevity.
Please login or sign up to comment.
Commenting guidelines